NR (Nicotinamide Riboside) is a vitamin B3–related pyridine nucleoside and NAD+ precursor that occurs in nutrient biology and is studied in humans mainly for NAD+ biomarker elevation, aging-related biology, cardiometabolic outcomes, neurological research, skeletal muscle physiology, and cognition (Review).
Human research on NR (Nicotinamide Riboside) most consistently shows that oral NR can increase blood NAD+ or NAD-related metabolites, while clinical-outcome evidence is more mixed across Cardiovascular Health, Diabetes and Glycemic Control, Muscle Health, Neurological Health, and Cognitive Health (Research) (Review). NAD+ means nicotinamide adenine dinucleotide, a cellular coenzyme that helps transfer electrons in energy metabolism and also serves as a substrate for enzymes involved in DNA repair, chromatin regulation, immune signaling, cellular senescence, and stress-response biology (Review). Overall, NR has moderate human evidence for NAD+ biomarker elevation and limited or mixed evidence for most clinical outcomes (Review).
Ingredient Identity
- Official name(s): Nicotinamide riboside; NR (Nicotinamide Riboside) (Review).
- Synonyms: Nicotinamide riboside chloride is the common studied salt form in several human trials; NIAGEN appears in some trial contexts as a studied ingredient form (Research).
- Classification: Vitamin B3 derivative, pyridine nucleoside, and NAD+ precursor (NIH ODS).
- CAS number: CAS identifiers vary by exact chemical form, and this article focuses on the human-studied ingredient identity rather than a single CAS-only definition.
- Endogenous vs exogenous: NR is connected to endogenous NAD+ metabolism and is also studied as an exogenous oral NAD+ precursor (Research).
Ingredient Snapshot
- Classification: NR (Nicotinamide Riboside) is a vitamin B3–related NAD+ precursor studied for its ability to raise NAD+ metabolites in humans (NIH ODS).
- Endogenous vs exogenous status: NR participates in NAD+ precursor biology, and oral NR has been studied as an exogenous way to increase NAD-related biomarkers (Research).
- Primary human research domains: Human research includes NAD+ pharmacokinetics, Aging and Longevity Research, Cardiovascular Health, Diabetes and Glycemic Control, Muscle Health, Neurological Health, Cognitive Health, and Kidney Health (Research) (Research).
- Common study formats: NR evidence includes pharmacokinetic studies, randomized placebo-controlled trials, crossover trials, open-label pilot studies, and combination-product trials (Research) (Research).
- Pharmacokinetic characterization status: Oral NR has human pharmacokinetic and biomarker evidence showing increases in blood NAD+ or NAD-related metabolites, with reported dose-response data from 100 mg/day, 300 mg/day, and 1000 mg/day oral NR chloride (Research).
- Regulatory context: In the U.S., FDA issued a “no questions” response to GRAS Notice No. 000635 for nicotinamide riboside chloride as a source of vitamin B3 in specified food uses (FDA).
- Regulatory context: In the EU, EFSA evaluated nicotinamide riboside chloride as a novel food and later assessed an extension of use in additional food categories (EFSA) (EFSA).
- Evidence maturity: Human evidence is strongest for NAD+ biomarker elevation and weaker for condition-specific clinical outcomes (Review).
Introduction
NR (Nicotinamide Riboside) is one of several vitamin B3–related compounds that can contribute to NAD+ metabolism, alongside nicotinic acid, nicotinamide, and related derivatives (NIH ODS). NR has been identified in nutrient biology, including research related to milk, but most human studies use controlled oral nicotinamide riboside chloride rather than ordinary food exposure (Research).
People look up NR because NAD+ is central to cellular energy chemistry and because NAD+-dependent enzymes participate in metabolism, DNA repair, chromatin regulation, immune function, and cellular stress responses (Review). Human trials have evaluated whether raising NAD-related biomarkers with oral NR translates into measurable outcomes in Aging and Longevity Research, Cardiovascular Health, Diabetes and Glycemic Control, Muscle Health, Neurological Health, and Cognitive Health (Review).
This article is informational only, describes NR as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- NR (Nicotinamide Riboside) is a vitamin B3–related NAD+ precursor; in human studies, its most consistent effect is increasing NAD+ or NAD-related metabolites after oral intake (Research).
- NAD+ means nicotinamide adenine dinucleotide, a coenzyme that supports cellular energy chemistry and NAD+-dependent enzymes involved in DNA repair, chromatin regulation, immune signaling, and stress-response biology (Review).
- NR is not the same as NMN (Nicotinamide Mononucleotide), NMNH (Reduced Nicotinamide Mononucleotide), or nicotinamide; these compounds differ by chemical structure, metabolic entry point, and human evidence base (Review) (Research).
- The strongest human evidence for NR is biomarker evidence, not broad proof of clinical benefit across aging, metabolic, neurological, or cardiovascular outcomes (Research) (Review).
- In an 8-week dose-response trial, 100 mg/day, 300 mg/day, and 1000 mg/day NR increased whole-blood NAD+ by about 22%, 51%, and 142%, respectively, within 2 weeks (Research).
- In Diabetes and Glycemic Control, randomized trials using 2000 mg/day NR for 12 weeks in obesity and insulin resistance did not show clear improvements in insulin sensitivity, glucose metabolism, or endocrine pancreatic outcomes (Research) (Research).
- Combination studies using NR with pterostilbene, resveratrol, or exercise cannot be interpreted as NR-only evidence because co-interventions may influence outcomes (Research) (Research).
Human Research Findings by Condition
Aging and Longevity Research
Human Aging and Longevity Research on NR has mainly tested whether oral NR raises NAD+ biomarkers and influences aging-related physiological measures in older adults or rare-aging contexts (Research) (Research). The clearest human signal is NAD+ biomarker elevation; evidence for broad aging-related clinical benefit remains limited because many studies are small, short, or exploratory (Review).
Key human study
Dose studied: 500 mg twice daily
Population: Healthy middle-aged and older adults
Duration: 6 weeks
Researchers studied chronic oral NR in healthy middle-aged and older adults and reported that NR was well tolerated and increased NAD+ measures, with exploratory findings in vascular markers such as systolic blood pressure and arterial stiffness in some analyses (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: NR dose studied in a double-blind randomized crossover design
Population: People with Werner syndrome
Duration: Crossover intervention period
A 2025 randomized crossover trial evaluated NR in Werner syndrome and reported NAD+ augmentation with improvements in selected clinical markers, but the rare-disease population limits generalization to typical aging (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Diabetes and Glycemic Control
Human Diabetes and Glycemic Control research has tested NR in obesity, insulin resistance, and endocrine pancreatic function, with generally neutral clinical findings despite NAD+ precursor activity (Research) (Research). This area is important because it includes controlled trials with metabolic endpoints rather than biomarker outcomes alone.
Key human study
Dose studied: 1000 mg twice daily
Population: Obese insulin-resistant men
Duration: 12 weeks
Researchers tested NR in obese insulin-resistant men and reported that it appeared safe but did not clearly improve insulin sensitivity or whole-body glucose metabolism (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 1000 mg twice daily
Population: Men with obesity and insulin resistance
Duration: 12 weeks
A related randomized trial analysis examined endocrine pancreatic outcomes and did not find clear improvement in glucose tolerance, beta-cell secretory capacity, alpha-cell function, incretin hormones, or plasma bile-acid outcomes (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: (Research)
Cardiovascular Health
Cardiovascular Health research on NR includes trials in healthy older adults, clinically stable heart failure, hypertension with exercise, and peripheral artery disease (Research) (Research). The evidence is promising in selected contexts but not definitive because some studies are exploratory, safety-focused, open-label, or combination-based (Review).
Key human study
Dose studied: NR with and without resveratrol; NR-alone arm included
Population: People with peripheral artery disease
Duration: 6 months
A randomized trial in people with peripheral artery disease evaluated NR with and without resveratrol for walking performance, and the NR-alone arm reportedly improved 6-minute walk distance versus placebo at 6 months (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 1000 mg twice daily
Population: Clinically stable heart failure with reduced ejection fraction
Duration: Safety and tolerability trial period
A 30-participant heart-failure trial studied NR for safety and tolerability in clinically stable heart failure with reduced ejection fraction, so it supports feasibility and tolerability interpretation more than clinical efficacy conclusions (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Muscle Health
Human Muscle Health studies have evaluated skeletal-muscle NAD+ metabolites, mitochondrial respiration, metabolic flexibility, and muscle regeneration after injury (Research) (Research). The overall evidence is mixed because NR can change NAD-related muscle biomarkers, but human trials have not consistently shown improvements in mitochondrial function, regeneration, or performance-related outcomes (Review).
Key human study
Dose studied: 1000 mg/day
Population: Aged men
Duration: 21 days
Researchers reported that 1000 mg/day NR for 21 days increased the aged human skeletal-muscle NAD+ metabolome and was associated with transcriptomic and inflammatory-signature changes, but the study did not establish broad functional improvement (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: NR + pterostilbene combination
Population: Older individuals after experimental muscle injury
Duration: Short-term post-injury study
A randomized placebo-controlled trial tested NR plus pterostilbene after muscle injury and did not establish clear improvement in muscle-regeneration outcomes, making the clinical muscle-regeneration signal uncertain (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
Neurological Health
Neurological Health research on NR includes Parkinson’s disease trials that measured NAD-related biomarkers, brain metabolism, and safety at standard and high-dose exposure (Research) (Research). The evidence is early-stage because the trials are phase I or safety-focused and do not establish disease-modifying clinical benefit.
Key human study
Dose studied: 1000 mg/day
Population: People with Parkinson’s disease
Duration: 30 days
A phase I randomized trial reported that 1000 mg/day NR for 30 days increased brain NAD-related measures and altered cerebral metabolism in people with Parkinson’s disease, while clinical implications remained exploratory (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 3000 mg/day
Population: People with Parkinson’s disease
Duration: 4 weeks
A high-dose randomized safety trial reported that 3000 mg/day NR for 4 weeks augmented the blood NAD metabolome and supported further phase II testing with safety monitoring, but it was not designed as definitive efficacy evidence (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Cognitive Health
Cognitive Health research on NR includes a pilot randomized trial in older adults with mild cognitive impairment that measured NAD+, cognition, epigenetic markers, and cerebral blood-flow outcomes (Research). Current evidence is limited because the trial showed biomarker effects but did not show a clear cognitive improvement.
Key human study
Dose studied: 2000 mg/day
Population: Older adults with mild cognitive impairment
Duration: 10 weeks
NR increased blood NAD+ and was well tolerated in older adults with mild cognitive impairment, but it did not clearly improve cognition during the 10-week study period (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Kidney Health
Kidney Health research includes a randomized placebo-controlled study of NR with pterostilbene in acute kidney injury, where the combination increased NAD+ but was not NR alone (Research). This evidence is exploratory and combination-specific.
Key human study
Dose studied: NR + pterostilbene combination
Population: Patients with acute kidney injury
Duration: Randomized intervention period
Researchers tested NR plus pterostilbene in acute kidney injury and reported increased NAD+ in the intervention context, but the combination design prevents clear attribution to NR alone (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human NR studies mainly use oral supplemental nicotinamide riboside chloride, with dose-response biomarker trials, pharmacokinetic studies, condition-specific randomized trials, and combination-product trials (Research) (Research). Human NR trials summarized here include 100 mg/day, 250 mg/day, 300 mg/day, 500 mg/day combination-context NR, 1000 mg/day, 2000 mg/day, and 3000 mg/day, while ordinary dietary NR intake ranges are not well quantified in the cited clinical literature (Research).
100 mg/day oral NR:
A randomized dose-response study in overweight but otherwise healthy adults included 100 mg/day, 300 mg/day, and 1000 mg/day oral NR chloride groups (Research). The 100 mg/day group represents the lowest documented oral NR exposure in the human trial evidence summarized here. Researchers measured whole-blood NAD+ and related metabolites rather than disease outcomes. Whole-blood NAD+ increased by about 22% within 2 weeks at 100 mg/day and remained elevated during the 8-week study. This dose band is most useful for understanding biomarker responsiveness at low supplemental exposure.
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: This was a biomarker study in overweight but otherwise healthy adults, not a clinical-outcome trial.
250 mg/day to 2000 mg/day oral NR escalation:
A small open-label pharmacokinetic study escalated NR from 250 mg/day to 1000 mg twice daily in healthy volunteers (Research). Researchers measured blood NAD+ and NAD-related metabolites during repeated exposure and 24-hour pharmacokinetic testing. NR was reported as well tolerated and increased circulating NAD+ measures in this small study. Blood NR appeared to reach steady state by Day 9 after two days at 1000 mg twice daily, while whole-blood NAD+ remained relatively stable across the final 12-hour dosing interval. This dose band is useful for understanding how escalating oral NR exposure affects NAD+ biomarkers in humans.
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: The study was small and open-label, so it is mainly useful for pharmacokinetic and tolerability context.
300 mg/day oral NR:
The 8-week dose-response trial included 300 mg/day oral NR chloride and reported a whole-blood NAD+ increase of about 51% within 2 weeks (Research). Participants were overweight but otherwise healthy adults. The NAD+ increase at 300 mg/day was larger than the 22% increase at 100 mg/day and smaller than the 142% increase at 1000 mg/day. This dose band shows dose-responsive biomarker elevation across low-to-moderate supplemental exposures. It does not show that a biomarker increase necessarily translates into a clinical health outcome.
Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: Biomarker elevation should not be interpreted as clinical efficacy by itself.
250 mg NR + 50 mg pterostilbene and 500 mg NR + 100 mg pterostilbene:
A randomized double-blind placebo-controlled study tested NR in combination with pterostilbene at 250 mg NR + 50 mg pterostilbene and 500 mg NR + 100 mg pterostilbene (Research). The study measured NAD+ changes and tolerability during repeat dosing. NAD+ increased in the combination groups, and the study reported no serious adverse events in the tested context. This dose band is useful for combination-context interpretation but cannot isolate NR-specific effects. It also shows why co-ingredients matter when interpreting NR studies.
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: The combination design limits attribution to NR alone.
1000 mg/day oral NR:
Several human studies used 1000 mg/day NR, including trials in healthy older adults, aged skeletal muscle, Parkinson’s disease, and overweight or obese adults (Research) (Research). In the 8-week dose-response trial, 1000 mg/day increased whole-blood NAD+ by about 142% within 2 weeks (Research). In healthy middle-aged and older adults, NR elevated NAD+ and was reported as well tolerated over 6 weeks. In Parkinson’s disease, a phase I study reported increased brain NAD-related measures and altered cerebral metabolism after 30 days. This dose band is the most broadly represented across human condition studies in the evidence summarized here.
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Biomarker effects are more consistent than clinical outcome effects.
2000 mg/day oral NR:
Several clinical studies used 2000 mg/day, commonly as 1000 mg twice daily, in obesity and insulin resistance, heart failure, and mild cognitive impairment (Research) (Research). In obese insulin-resistant men, 2000 mg/day for 12 weeks appeared safe but did not clearly improve insulin sensitivity or whole-body glucose metabolism. In mild cognitive impairment, 2000 mg/day for 10 weeks increased blood NAD+ and was well tolerated but did not clearly improve cognition. In heart failure with reduced ejection fraction, 1000 mg twice daily was studied for safety and tolerability. This dose band shows that higher oral exposure can raise biomarkers without reliably producing clinical outcome improvements across populations.
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Several trials at this exposure were small or focused on tolerability and biomarkers.
3000 mg/day oral NR:
A high-dose randomized safety trial in Parkinson’s disease studied 3000 mg/day NR for 4 weeks (Research). Researchers reported augmentation of the blood NAD metabolome and support for further phase II testing with safety monitoring. This is the highest documented human oral NR exposure in the summarized human trial evidence. The study is important for high-dose tolerability context but does not establish clinical efficacy for Parkinson’s disease. Interpretation should remain specific to the study design and population.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: High-dose findings are population- and trial-specific and should not be generalized as dosing advice.
Key Takeaways from Human Research
- Oral NR has repeatedly increased NAD+ or NAD-related metabolites in human blood, making biomarker elevation the most consistent human finding (Research).
- In one 8-week dose-response trial, 100 mg/day, 300 mg/day, and 1000 mg/day NR increased whole-blood NAD+ by about 22%, 51%, and 142%, respectively, within 2 weeks (Research).
- Clinical outcome findings are less consistent than biomarker findings, especially in Diabetes and Glycemic Control, Cognitive Health, and Muscle Health (Research) (Research).
- Cardiovascular Health evidence includes exploratory vascular-marker findings and a peripheral artery disease trial reporting improved 6-minute walk distance at 6 months with NR alone, but broader cardiovascular conclusions remain limited (Research).
- Neurological Health studies in Parkinson’s disease show NAD-related biomarker and metabolic effects after 30 days at 1000 mg/day and after 4 weeks at 3000 mg/day, but the trials are early-stage and not definitive clinical-efficacy evidence (Research) (Research).
- NR differs from NMN (Nicotinamide Mononucleotide), NMNH (Reduced Nicotinamide Mononucleotide), and nicotinamide because these compounds enter NAD+ metabolism through different chemical and enzymatic contexts (Review).
Origin & Natural Occurrence
NR is part of vitamin B3 and NAD+ precursor biology, meaning it is biochemically related to the body’s pathways for making NAD+ (Review). NIH ODS describes niacin as a generic term that includes nicotinic acid, nicotinamide, and related derivatives such as nicotinamide riboside (NIH ODS).
NR has been identified in nutrient biology, including research related to milk (Research). The human trial literature summarized in this article mainly studies manufactured oral nicotinamide riboside chloride rather than quantified ordinary dietary NR exposure (Research).
Commercial and regulatory reviews specifically evaluate nicotinamide riboside chloride as a source of vitamin B3 in food or novel-food contexts (FDA) (EFSA). This means clinical trial exposure should be understood as controlled ingredient exposure, not as a direct proxy for ordinary food intake.
How It Behaves in the Body
In plain language, NR is studied because it can help supply the body with building blocks for NAD+, short for nicotinamide adenine dinucleotide (Review). NAD+ helps cells transfer electrons during energy-related chemistry and also supports enzymes that regulate cell maintenance, stress responses, and repair biology (Review).
NAD+ has two major roles that matter for interpreting NR research. First, NAD+ acts as a redox cofactor, meaning it helps shuttle electrons in reactions that convert nutrients into usable cellular energy (Review). Second, NAD+ acts as a substrate for enzymes such as sirtuins, poly(ADP-ribose) polymerases, CD38, and related NAD+-consuming enzymes, which connect NAD+ availability to DNA repair, chromatin regulation, immune signaling, cellular senescence, and stress-response pathways (Review).
Mechanistically, NR is converted through NAD+ salvage metabolism after phosphorylation by nicotinamide riboside kinases into NMN (Nicotinamide Mononucleotide), which can then contribute to NAD+ synthesis (Review). This pathway helps explain why oral NR can raise NAD-related biomarkers in blood and selected tissues, but it does not prove that every NAD+-linked pathway improves clinically in humans (Research).
PBMC means peripheral blood mononuclear cell, a category of immune cells in blood that researchers sometimes use to measure intracellular NAD+ responses (Research). PBMC NAD+, whole-blood NAD+, blood NR, and brain NAD are different measurements, so their timing values should not be treated as interchangeable.
The clearest human finding is that oral NR can raise NAD+ or NAD-related metabolites; the less certain question is whether those biomarker changes reliably produce clinical improvements in specific conditions (Review). This distinction is central to interpreting NR because NAD+ biology is broad, while clinical trial evidence is still outcome-specific and uneven.
Absorption & Delivery Formats
Oral immediate-release: The human evidence summarized here primarily evaluates oral NR or oral nicotinamide riboside chloride, including pharmacokinetic, dose-response, and condition-specific trials (Research) (Research). Oral NR has repeatedly increased blood NAD+ or NAD-related metabolites in human studies (Research).
Oral extended-release: The summarized evidence does not include a distinct human extended-release NR trial. Extended-release claims should not be inferred from standard oral NR trials.
Sublingual: The summarized evidence does not include a sublingual NR human pharmacokinetic study. Sublingual absorption claims are therefore outside the human evidence base used here.
Transdermal: The summarized evidence does not include a transdermal NR human study. The article should not be used to infer transdermal NR absorption.
Injectable / IV: The summarized evidence does not include injectable or IV NR trials. The studied human exposure context is oral supplementation, not parenteral administration (Research).
Quick Facts at a Glance
Onset (reported): In a single-person human pilot using 1000 mg oral NR, PBMC NAD+ was unchanged during the first 2.7 hours, rose at 4.1 hours, and peaked at 7.7–8.1 hours at about 2.7-fold above baseline (Research). PBMC means peripheral blood mononuclear cell, so this finding describes intracellular NAD+ in a blood immune-cell fraction, not symptom onset or plasma NR onset (Research).
Time to peak (Tmax): NR pharmacokinetic timing should be reported by analyte because NR itself, PBMC NAD+, whole-blood NAD+, and brain NAD are different measurements. In the single-person pilot, PBMC NAD+ peaked at 7.7–8.1 hours after 1000 mg oral NR, while an open-label PK study found that blood NR itself was short-lived and that whole-blood NAD+ behaved more like a sustained biomarker after repeated dosing (Research) (Research).
Half-life (t½): A single half-life should not be assigned to “NR” broadly because NR, NAD+, NAAD, methylated nicotinamide metabolites, and tissue NAD pools behave differently. The 8-person open-label PK study described NR itself as having a “rather short elimination half-life,” while a 2026 NAD-brain pharmacokinetic study reported that blood NAD increased slowly, plateaued after about 2 weeks, and declined with similarly slow kinetics after stopping oral NAD precursor supplementation (Research) (Research).
Typical duration: Human NR studies range from single-dose 24-hour pharmacokinetic monitoring to repeated interventions of 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, and 6 months, depending on the population and endpoint (Research) (Research). The clearest duration-supported finding is NAD+ biomarker elevation; clinical outcome evidence depends strongly on condition, endpoint, and study length.
Absorption routes studied: Oral administration is the dominant studied route in the human NR evidence base, with reported human doses including 100 mg/day, 250 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, and 3000 mg/day (Research) (Research). Sublingual, transdermal, injectable, and IV NR formats are not established by the studies summarized here.
Formulation differences: Human studies include NR alone and combination products such as NR + pterostilbene and NR + resveratrol (Research) (Research). Combination studies should not be interpreted as NR-only evidence because co-ingredients may influence outcomes.
Variability drivers: In the 8-person open-label PK study, individual whole-blood NAD+ increases after dose escalation to 1000 mg twice daily ranged from 35% to 168% above baseline, showing substantial person-to-person variability (Research). Study results may vary by population, dose, duration, tissue or blood compartment measured, and whether the endpoint is a biomarker or a clinical outcome (Review).
Tolerance / adaptation: Human studies report tolerability across short-to-medium study periods, but they do not establish a precise tolerance model showing whether NAD+ response diminishes with repeated NR exposure (Research) (Research). The most useful numeric context is that one PK study found blood NR appeared to reach steady state by Day 9 after two days at 1000 mg twice daily, while whole-blood NAD+ remained relatively constant across the final 12-hour dosing interval (Research).
Evidence strength snapshot: NR has moderate evidence for raising NAD+ biomarkers, because multiple human studies show blood NAD+ or NAD-metabolome increases after oral dosing (Research). NR has limited or mixed evidence for clinical outcomes, because controlled trials have produced neutral, exploratory, or population-specific findings in Diabetes and Glycemic Control, Cognitive Health, Muscle Health, Cardiovascular Health, and Neurological Health (Review).
Other Physiological Contexts Studied (If Applicable)
- Acute kidney injury: NR plus pterostilbene was studied in acute kidney injury and increased NAD+ in a combination-product context, but the evidence cannot isolate NR alone (Research).
- Hypertension and exercise: A 2025 pilot randomized trial tested NR combined with exercise in middle-aged and older adults with hypertension, so the findings should be interpreted as combination-context evidence rather than NR-only evidence (Research).
- Peripheral artery disease vascular and cognitive outcomes: A 2025 pilot open-label study evaluated 1 g/day NR for 4 weeks in older adults with peripheral artery disease, vascular function, and cognitive outcomes, but the open-label design limits causal certainty (Research).
Safety, Interactions & Regulation
Human studies have generally reported short-term tolerability of oral NR across healthy adults, overweight adults, older adults, people with obesity or insulin resistance, mild cognitive impairment, heart failure, and Parkinson’s disease contexts (Research) (Research). This safety evidence is strongest for the studied populations and study durations ranging from acute PK monitoring to 12 weeks, with some condition-specific research extending to 6 months (Research).
Adverse-effect interpretation is limited because many NR trials are small, short, or focused primarily on biomarkers rather than rare adverse events (Review). Higher-dose NR has been studied in Parkinson’s disease at 3000 mg/day for 4 weeks with safety monitoring, but this does not establish universal high-dose safety across all populations (Research).
The summarized human evidence does not identify a well-established medication-interaction profile for NR. Interaction considerations remain theoretical or population-specific unless directly studied in a clinical trial.
Pregnant people, children, people with serious medical conditions, and people using medications are not well represented across the summarized NR trials. This limits confidence for population-specific safety conclusions.
In the U.S., FDA issued a “no questions” letter for GRAS Notice No. 000635 for nicotinamide riboside chloride as a source of vitamin B3 in specified food and beverage uses (FDA). FDA’s GRAS notice materials describe an intended food-use context and should not be read as an FDA disease-treatment approval (FDA).
In the EU, EFSA issued a scientific opinion on the safety of nicotinamide riboside chloride as a novel food (EFSA). EFSA also evaluated an extension of use for nicotinamide riboside chloride in additional food categories (EFSA).
Evidence Overview
The human evidence base for NR (Nicotinamide Riboside) is strongest for NAD+ biomarker elevation after oral intake and weaker for condition-specific clinical outcomes in Diabetes and Glycemic Control, Cognitive Health, Muscle Health, Cardiovascular Health, and Neurological Health (Research) (Review). The evidence includes pharmacokinetic studies, randomized placebo-controlled trials, crossover trials, open-label pilot studies, and combination-product trials (Research) (Research). Confidence is not higher because many trials are small, short, biomarker-focused, population-specific, or affected by combination designs.
The biological rationale for NR is credible because NAD+ supports redox metabolism and NAD+-dependent enzymes involved in DNA repair, chromatin regulation, immune function, cellular senescence, and stress-response biology (Review). However, NAD+ is involved in many pathways, so increasing NAD-related biomarkers does not automatically predict a clinical effect in every condition (Review).
In metabolic-health research, controlled trials in obesity and insulin resistance have not shown clear improvements in insulin sensitivity, whole-body glucose metabolism, or endocrine pancreatic outcomes after 2000 mg/day NR for 12 weeks (Research) (Research). These neutral findings are important because they show that NAD+ biomarker plausibility and clinical metabolic benefit are separate questions.
Cardiovascular Health evidence is more varied. Healthy older-adult research reported exploratory vascular-marker findings over 6 weeks, a peripheral artery disease trial reported improved 6-minute walk distance at 6 months with NR alone, and heart-failure research has focused on safety and tolerability rather than definitive efficacy (Research) (Research) (Research).
Neurological Health and Cognitive Health evidence remains early. Parkinson’s disease trials show NAD-related biomarker and metabolic effects after 30 days at 1000 mg/day and 4 weeks at 3000 mg/day, while mild cognitive impairment research showed NAD+ elevation after 10 weeks without clear cognitive improvement (Research) (Research).
Evidence Confidence Classification
Moderate for NAD+ biomarker elevation and Limited / Mixed for most clinical outcomes is the best overall evidence classification for NR (Nicotinamide Riboside), because multiple human studies show NAD-related biomarker increases but clinical outcomes remain inconsistent across conditions (Research) (Review).
NR has credible human pharmacokinetic and biomarker evidence because several studies report increased NAD+ or NAD-related metabolites after oral intake, including dose-response data from 100 mg/day to 1000 mg/day and clinical trial exposure up to 3000 mg/day (Research) (Research). Clinical confidence is lower because many trials report neutral outcomes, exploratory signals, or population-specific findings that need replication (Research) (Research). Mechanistic evidence supports continued study, but larger and longer trials with clinically meaningful endpoints are needed to strengthen conclusions (Review).
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- NMN (Nicotinamide Mononucleotide): NMN is a phosphorylated NAD+ precursor that is one metabolic step closer to NAD+ than NR, and human and preclinical research compare it with NR as another NAD+-raising compound (Review).
- NMNH (Reduced Nicotinamide Mononucleotide): NMNH is the reduced form of NMN and has been reported in experimental research as a potent NAD+ precursor with a different metabolic pathway from NR and NMN, but human evidence is much less developed (Research).
- Nicotinamide: Nicotinamide, also called niacinamide, is a vitamin B3 form included under the broader niacin family, and it differs from NR because it enters NAD+ metabolism through nicotinamide salvage rather than as a riboside nucleoside (NIH ODS).
- Nicotinic acid: Nicotinic acid is another vitamin B3 form and differs from nicotinamide and NR in clinical and biochemical behavior (NIH ODS).
- Tryptophan: Tryptophan can contribute to niacin-related metabolism through de novo pathways, but it is not structurally the same as NR (NIH ODS).
- Resveratrol: Resveratrol has been studied with NR in peripheral artery disease research, but combination results should not be treated as NR-only evidence (Research).
- Pterostilbene: Pterostilbene has been studied with NR in NRPT trials, which makes interpretation combination-specific (Research).
- Coenzyme Q10: Coenzyme Q10 is often discussed near mitochondrial-health topics, but it is not an NAD+ precursor.
- Alpha-lipoic acid: Alpha-lipoic acid is sometimes grouped with metabolic or redox-support ingredients, but it is not a vitamin B3 derivative.
- Creatine: Creatine is relevant to cellular energy buffering, but it does not serve as an NAD+ precursor.
Medical / pharma comparator categories:
- Vitamin B3 repletion therapies
- Cardiometabolic medications
- Diabetes and insulin-sensitizing medications
- Heart-failure therapies
- Parkinson’s disease medications
- Cognitive-disorder therapeutics
- Peripheral artery disease rehabilitation or vascular therapies
Combination Context
NR (Nicotinamide Riboside) + Pterostilbene:
NR plus pterostilbene has been studied as NRPT in randomized human trials, including healthy-adult NAD+ biomarker research and muscle-regeneration research after injury (Research) (Research). The combination increased NAD+ in healthy adults, but muscle-regeneration findings did not establish clear improvement after injury. The main limitation is that pterostilbene makes the findings combination-specific rather than NR-only evidence.
NR (Nicotinamide Riboside) + Resveratrol:
NR with and without resveratrol was studied in peripheral artery disease, where NR-alone and combination contexts were evaluated for walking performance (Research). The NR-alone arm reportedly improved 6-minute walk distance versus placebo at 6 months, but the combination context still requires careful interpretation. The main limitation is that co-ingredient and disease-specific factors complicate broad conclusions.
NR (Nicotinamide Riboside) + Exercise:
NR combined with exercise has been evaluated in a pilot randomized trial in middle-aged and older adults with hypertension (Research). This combination was studied because both NAD+ biology and exercise adaptation are relevant to vascular and metabolic aging research. The main limitation is that combination designs cannot determine how much of any observed effect is due to NR, exercise, or their interaction.
FAQ
What is NR?
NR is NR (Nicotinamide Riboside), a vitamin B3–related pyridine nucleoside and NAD+ precursor (Review). It is studied because oral NR can increase NAD+ or NAD-related metabolites in humans (Research). NR is related to but chemically different from NMN (Nicotinamide Mononucleotide), NMNH (Reduced Nicotinamide Mononucleotide), and nicotinamide (Review).
What does NAD+ do?
NAD+ means nicotinamide adenine dinucleotide, a coenzyme that helps cells transfer electrons during redox reactions and supports enzymes that regulate cell maintenance (Review). NAD+ also serves as a substrate for enzymes such as sirtuins, PARPs, CD38, and related NAD+-consuming enzymes (Review). These roles connect NAD+ to metabolism, DNA repair, chromatin regulation, immune function, cellular senescence, and stress-response biology (Review).
What is PBMC NAD+?
PBMC NAD+ means NAD+ measured inside peripheral blood mononuclear cells, which are a group of immune cells found in blood (Research). PBMC NAD+ is not the same measurement as blood NR, whole-blood NAD+, plasma metabolites, or brain NAD (Research) (Research). This distinction matters because PBMC NAD+ may peak at a different time than blood NR itself.
How is NR different from NMN, NMNH, and nicotinamide?
NR differs from NMN (Nicotinamide Mononucleotide), NMNH (Reduced Nicotinamide Mononucleotide), and nicotinamide because each compound has a different chemical structure and metabolic route into NAD+ biology (Review). NR is a riboside nucleoside that can be phosphorylated into NMN before contributing to NAD+ synthesis (Review). NMNH is a reduced form of NMN that experimental research identifies as a potent NAD+ precursor through a different pathway, but human evidence is far less developed than for NR (Research). Nicotinamide is a vitamin B3 form that belongs to the broader niacin family and enters NAD+ metabolism through nicotinamide salvage rather than as a riboside nucleoside (NIH ODS).
What does human research study NR for?
Human research studies NR mainly for NAD+ biomarker elevation, Aging and Longevity Research, Cardiovascular Health, Diabetes and Glycemic Control, Muscle Health, Neurological Health, and Cognitive Health (Review). Trials have included healthy adults, older adults, people with obesity or insulin resistance, Parkinson’s disease, mild cognitive impairment, heart failure, and peripheral artery disease (Research) (Research). Many studies measure biomarkers rather than definitive clinical endpoints (Research).
What are the best-supported uses?
The best-supported human finding is that oral NR can increase blood NAD+ or NAD-related metabolites (Research). In one 8-week trial, 100 mg/day, 300 mg/day, and 1000 mg/day NR increased whole-blood NAD+ by about 22%, 51%, and 142%, respectively, within 2 weeks (Research). Clinical-outcome support is more preliminary and condition-specific, including emerging evidence in peripheral artery disease walking performance (Research).
Where is evidence mixed or limited?
Evidence is mixed or limited for Diabetes and Glycemic Control, Cognitive Health, Muscle Health, and broad clinical aging outcomes (Research) (Research). Obesity and insulin-resistance trials using 2000 mg/day for 12 weeks did not show clear improvement in insulin sensitivity or endocrine pancreatic outcomes (Research). Muscle studies show NAD-related molecular changes but inconsistent functional or mitochondrial outcomes (Review).
How quickly does NR act?
NR can increase NAD-related biomarkers within hours in some pharmacokinetic settings, but the timing depends on the analyte measured (Research). In a single-person pilot, PBMC NAD+ rose by 4.1 hours and peaked at 7.7–8.1 hours after 1000 mg oral NR (Research). This is biomarker onset, not symptom onset or a universal clinical-onset time.
What affects absorption and variability?
Absorption and biomarker response can vary by dose, study duration, population, formulation, and whether NR is studied alone or in combination (Research) (Research). In one open-label PK study, individual whole-blood NAD+ increases after escalation to 1000 mg twice daily ranged from 35% to 168% above baseline (Research). Combination products such as NR plus pterostilbene or resveratrol cannot be interpreted as NR-only evidence (Research).
Is tolerance reported?
The summarized evidence does not establish a clear tolerance model for NR, meaning it does not show whether repeated NR produces diminishing biological response over time. Several studies report short-term tolerability, but tolerability is different from tolerance or adaptation (Research). One PK study found blood NR appeared to reach steady state by Day 9 after two days at 1000 mg twice daily, but this is not the same as proving long-term tolerance or loss of response (Research).
Why do studies disagree?
NR studies disagree because they differ in dose, duration, population, endpoint, and measured analyte, including NR itself, PBMC NAD+, whole-blood NAD+, tissue NAD, or clinical outcomes (Review). NAD+ biomarker elevation is more consistent than improvements in insulin sensitivity, cognition, muscle function, or cardiovascular outcomes (Research) (Research). Some studies also use combinations such as NR plus pterostilbene or resveratrol, which complicates attribution to NR alone (Research).
What ingredients is NR commonly combined with and why?
NR has been studied with pterostilbene and resveratrol in human research contexts (Research) (Research). These combinations are usually studied because researchers are interested in NAD+ biology, vascular function, aging-related pathways, or metabolic signaling. Combination evidence should not be treated as NR-only evidence because co-ingredients can influence results.
What foods naturally contain NR?
NR has been identified in nutrient biology, including research related to milk (Research). The summarized evidence does not provide a robust quantified dietary intake range for ordinary food intake. Human clinical trials generally study manufactured oral nicotinamide riboside chloride rather than natural dietary NR exposure (Research).
How is NR regulated?
In the U.S., FDA issued a “no questions” response to GRAS Notice No. 000635 for nicotinamide riboside chloride as a source of vitamin B3 in specified food uses (FDA). In the EU, EFSA evaluated nicotinamide riboside chloride as a novel food and assessed an extension of use in additional food categories (EFSA) (EFSA). These regulatory sources address food or novel-food ingredient contexts rather than disease-treatment approval.
Resources
Trammell et al., 2016 — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC5062546/
Airhart et al., 2017 — Research — https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186459
Martens et al., 2018 — Research — https://pubmed.ncbi.nlm.nih.gov/29599478/
Dollerup et al., 2018 — Research — https://pubmed.ncbi.nlm.nih.gov/29992272/
Conze et al., 2019 — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/
Covarrubias et al., 2021 — Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
Imai and Guarente, 2014 — Review — https://pubmed.ncbi.nlm.nih.gov/24786309/
Zapata-Pérez et al., 2021 — Research — https://pubmed.ncbi.nlm.nih.gov/33724555/
Palmer et al., 2021 — Review — https://pubmed.ncbi.nlm.nih.gov/34553119/
NAD-brain pharmacokinetic study — Research — https://pubmed.ncbi.nlm.nih.gov/41858901/
FDA GRAS Notice No. 000635 — FDA — https://www.fda.gov/food/gras-notice-inventory/agency-response-letter-gras-notice-no-grn-000635
EFSA novel food opinion — EFSA — https://pmc.ncbi.nlm.nih.gov/articles/PMC7009190/
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
